Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Legend Biotech (NAS:LEGN) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Legend Biotech Forward PE Ratio Related Terms
Legend Biotech Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Legend Biotech's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Legend Biotech Forward PE Ratio Chart
Legend Biotech Annual Data
Trend
2025-12
Forward PE Ratio
52.52
Legend Biotech Quarterly Data
2024-09
2025-09
2025-12
2026-03
Forward PE Ratio
1,000.00
56.56
52.52
83.17
LEGN vs TVTX, ORKA, CRSP: Forward PE Ratio Comparison
For the Biotechnology subindustry, Legend Biotech's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Legend Biotech's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Legend Biotech (LEGN) has a Forward PE Ratio of 383.79 as of Jul. 18, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Legend Biotech and its competitors. According to the industry distribution chart, Legend Biotech ranks #338 out of 354 companies in the Biotechnology industry, placing it in the top 95.5%.
Is Legend Biotech's Forward PE Ratio too high?
Legend Biotech's current Forward PE Ratio is 383.79. The Biotechnology industry median Forward PE Ratio is 21.97. Legend Biotech's value of 383.79 is 1646.9% above this industry median. Based on the distribution chart, Legend Biotech ranks #338 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Legend Biotech has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Forward PE Ratio compare to TVTX and ORKA?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #338 out of 354 companies for Forward PE Ratio. This places Legend Biotech in the lower half of its industry. The industry median Forward PE Ratio is 21.97. Legend Biotech's value of 383.79 is 1646.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.97, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Legend Biotech's current Forward PE Ratio of 383.79 is 1646.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Legend Biotech and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Legend Biotech's current Forward PE Ratio is 383.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $100.26, compared to a current price of $22.26 — trading 77.8% below its estimated fair value. The current Forward PE Ratio is 383.79 and 1646.9% above the Biotechnology industry median of 21.97. Legend Biotech's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Forward PE Ratio is 383.79 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Legend Biotech (LEGN) Overvalued in 2026?
Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued.
The current stock price of $22.26 is trading 77.8% below its estimated GF Value™ of $100.26.
GuruFocus considers Legend Biotech to be Possible Value Trap.
Key valuation signals for LEGN:
Forward PE Ratio: 383.79
GF Value™: $100.26 vs. price of $22.26 (77.8% below fair value)
Industry Position: 1646.9% above the Biotechnology median (#338 of 354)
No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score
Get the complete analysis for LEGN
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEGN has been successfully added to your 
